Howard M. Mackey
Genentech · 50 works · 4,183 citations · h-index 14
Top works
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
- Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer
- Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease
- Abstract B001: Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab
- A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
- The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort
- Bevacizumab in patients with advanced platinum-resistant ovarian cancer
- Induction of a neural phenotype in a serotonergic endocrine cell derived from the neural crest
- 355 POSTER Updated safety and efficacy data from a first-in-human, first-in-class, phase I study of Hedgehog pathway antagonist, GDC-0449
- Abstract LB-138: Efficacy data of GDC-0449, a systemic Hedgehog pathway antagonist, in a first-in-human, first-in-class Phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients
- The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997-2010
- A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors
- Some Notable Properties of the Standard Oncology Phase I Design
- Power and sample size for random coefficient regression models in randomized experiments with monotone missing data
- Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial
- Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC).
- Sample size and threshold estimation for clinical trials with predictive biomarkers
- P2‐006: Exploratory Analyses of Cognitive Effects of Crenezumab in a Mild Alzheimer's Disease Subpopulation of a Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 2 Study (ABBY)
- An industry statistician's perspective on PHC drug development